



¹ Phase 2 open label extension study for WHIM ongoing

² Two oncology trials have concluded: P1b biomarker in melanoma and P1b in ccRCC. Final publications expected in 2H19

³ Intend to enter into a strategic partnership for future development and potential commercialization for mavorixafor for ccRCC and other potential immuno-oncology indications